No. 25A901
Eli Lilly and Company v. United States, et al., ex. rel., Ronald J. Streck
Tags: average-manufacturer-price false-claims-act medicaid-rebate pharmaceutical-regulation qui-tam statutory-interpretation
Latest Conference:
N/A
Question Presented (from Petition)
Question not identified.
The petition text provided is an "Application for an Extension of Time" to file a petition for certiorari, not a petition for certiorari itself. It does not contain a "Question(s) Presented" section. The document presents background facts and context about the case, but does not include the formal "Question Presented" section that would appear in an actual petition for a writ of certiorari.
Question Presented (AI Summary)
Whether a pharmaceutical manufacturer's objectively reasonable interpretation of an ambiguous Medicaid rebate statute can constitute a false claim under the False Claims Act when the government did not provide clear guidance
Docket Entries
2026-02-09
Application (25A901) granted by Justice Barrett extending the time to file until March 21, 2026.
2026-02-04
Application (25A901) to extend the time to file a petition for a writ of certiorari from February 19, 2026 to March 21, 2026, submitted to Justice Barrett.
Attorneys
Eli Lilly and Company
Erin E. Murphy — Clement & Murphy, PLLC, Petitioner
Erin E. Murphy — Clement & Murphy, PLLC, Petitioner
Ronald J. Streck
D. John Sauer — Solicitor General, Respondent
D. John Sauer — Solicitor General, Respondent